Andrew Geall

Andrew Geall is vice president of formulations, analytics and chemistry at Avidity Biosciences, where over the past four years he has helped pioneer the development of the company’s antibody-oligonucleotide conjugate delivery platform. He has over 20 years of professional experience in the development of drug delivery systems and is acknowledged as a pioneer in the fields of mRNA vaccines and nucleic acid delivery. Prior to joining Avidity, he worked in the vaccine division of Novartis from 2008 to 2015 and led the exploration of mRNA vaccines. In his role as RNA vaccine platform leader, he helped create a global team (USA/Italy) and was principal investigator on a Defense Advanced Research Project Agency (DARPA) contract to develop self-amplifying mRNA vaccines. Dr. Geall joined the vaccine division from Novartis Pharmaceuticals AG, where he was the global siRNA formulation team leader and responsible for the design and implementation of the siRNA delivery strategy. Prior to Novartis, he led formulation development activities at Vical. Dr. Geall currently serves as the chair of the SAB at Precision Nanosystems, a biotechnology company pioneering the development of microfluidic mixing for nanomedicine applications. Dr. Geall received his pharmacy degree and Ph.D. in non-viral gene deliveryfrom the University of Bath in the UK and completed his pre-registration training as a hospital pharmacist in the aseptic dispensing unit at St Helens and Knowsley Trust Hospitals.